Skip to main content

GeneGo Licenses Pathways Software to Invitrogen

NEW YORK, June 1 (GenomeWeb News) - GeneGo has licensed its pathways database and software system to Invitrogen, the companies said today.


The multi-year licensing agreement includes plans for a collaboration to develop new capabilities for the software. The companies did not disclose the financial details of the agreement.


Michael Stapleton, general manager and vice president of Invitrogen's bioinformatics business, said in a statement that the licensing deal would "help us in making bioinformatics an intrinsic part of Invitrogen's solutions set for life science research."


GeneGo, of St. Joseph, Mich., has developed a program, MetaCore, that includes a database of molecular cellular pathways and is designed to integrate data from different levels of cellular function, including membrane receptors, signal transduction, transcription factors, and effector networks. The target users are pharmaceutical scientists engaged in target selection and validation, biomarker identification, and toxicology, the company said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.